Twenty-four of 44 patients (55%) with IBD received drugs including G-CSF (n = 11), mesalazine (n = 5), G-CSF and mesalazine (n = 4), thalidomide (n = 2), adalimumab (n = 1), and G-CSF and adalimumab (n = 1) (eTable 5 in Supplement 2). This evidence concerns the gene CSF3 and inflammatory bowel disease.